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The transgenic E1-DN mice express a kinase-negative epidermal growth factor receptor in their pancreatic islets and are diabetic
from two weeks of age due to impaired postnatal growth of 𝛽-cell mass. Here, we characterize the development of hyperglycaemia-
induced renal injury in the E1-DN mice. Homozygous mice showed increased albumin excretion rate (AER) at the age of 10
weeks; the albuminuria increased over time and correlated with blood glucose. Morphometric analysis of PAS-stained histological
sections and electron microscopy images revealed mesangial expansion in homozygous E1-DNmice, and glomerular sclerosis was
observed in the most hyperglycaemic mice. The albuminuric homozygous mice developed also other structural changes in the
glomeruli, including thickening of the glomerular basement membrane and widening of podocyte foot processes that are typical
for diabetic nephropathy. Increased apoptosis of podocytes was identified as one mechanism contributing to glomerular injury. In
addition, nephrin expression was reduced in the podocytes of albuminuric homozygous E1-DN mice. Tubular changes included
altered epithelial cell morphology and increased proliferation. In conclusion, hyperglycaemic E1-DN mice develop albuminuria
and glomerular and tubular injury typical of human diabetic nephropathy and can serve as a new model to study the mechanisms
leading to the development of diabetic nephropathy.
1. Introduction
Diabetic nephropathy affects every third patient with type 1
diabetes [1]. Advances in the management of diabetes may
reduce or postpone the risk of renal complication [2], and,
indeed, the incidence of nephropathy in type 1 diabetes has
been reported to be declining [3]. Still, diabetic nephropathy
is an important cause of morbidity in patients with diabetes
and associates also with cardiovascular disease [4] and all-
cause mortality [5]. The number of patients needing renal
replacement therapy is rapidly increasing, mainly due to the
global increase in the prevalence of type 2 diabetes [6, 7].
The first clinical sign of diabetic nephropathy is microal-
buminuria [8], indicating an injury in the glomerular filtra-
tion barrier. The disease often progresses to macroalbumin-
uria (defined as urinary albumin excretion >300mg/24 h)
[9], and even nephrotic-range proteinuria is observed [10].
Subsequent decline in the glomerular filtration rate can lead
to end-stage renal disease [11].
Pathological characteristics of diabetic nephropathy con-
stitute predominantly of glomerular lesions [12]. Thickening
of the glomerular basement membrane (GBM) is observed
early in type 1 diabetes [13]. The most important pathologic
feature is mesangial expansion, which is correlated to clinical
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findings of nephropathy [14] and to progression in albumin
excretion [15]. The accumulation of mesangial matrix may
eventually lead to nodular glomerular sclerosis, described
first by Kimmelstiel andWilson [16]. In advanced nephropa-
thy, also tubular atrophy and interstitial fibrosis are observed
[17].
Glomerular epithelial cells, podocytes, form the glomeru-
lar filtration barrier together with endothelial cells and the
GBM. Both the structure and number of podocytes are
affected in diabetes. Widening of podocyte foot processes,
surrounding the glomerular capillaries, has been observed
in renal biopsies of diabetic patients with increased albumin
excretion [18, 19]. Reduced number of podocytes, reported
in both type 1 [20] and type 2 diabetes [21], can result from
podocyte detachment [22] or apoptosis [23].
The molecular pathways leading to albuminuria and
the pathologic glomerular alterations are far from completely
understood. There is an evident need for animal models for
studies of the pathogenesis and the potential treatment strate-
gies of diabetic nephropathy. The existing mouse models
include induction of diabetes by streptozotocin [24], natu-
rallymutatedmouse lines like db/db [25] andAkitamice [26],
and more recent genetically engineered models, for example,
Ove26 mice [27] and endothelial nitric oxide synthase defi-
cient diabetic mice [28]. Many of these models recapitulate
the features of early nephropathy, various degrees of albumin-
uria and mild-to-moderate mesangial expansion, but rarely
more advanced glomerulopathy [29, 30].
The homozygous transgenic mice expressing kinase-
negative epidermal growth factor receptor (EGF-R) under the
pancreatic duodenal homeobox-1 (pdx-1) promoter (E1-DN
mice) are diabetic due to impaired postnatal growth of 𝛽-
cell mass and subsequent reduced production of insulin [31].
Even the heterozygous E1-DN mice have impaired glucose
tolerance in intraperitoneal glucose tolerance test [31]. The
E1-DN mice are viable without insulin and can live up to
one year. Thus, they can serve as a model to study the effects
of long-term hyperglycaemia. The aim of this study was to
characterize the development of renal injury in the diabetic
E1-DN mice.
2. Materials and Methods
2.1. Animals. E1-DN mice in FVB background were gener-
ated previously [31]. The transgene comprised of a human
kinase-deficient EGF-R cDNA with a myc-tag and a growth
hormone polyA tail under mouse Pdx-1 promoter [31]. Mice
were genotyped by dot blot analysis as previously described,
and the homozygotes were identified based on blood glucose
levels [31, 32]. Animals were maintained according to the
principles of laboratory animal care, and the experiments
were approved by the National Animal Experiment Board.
Male E1-DN mice were examined, and male wild-type lit-
termates were used as controls. Kidney samples were also
collected from male nonlittermate controls of the same
mouse strain in the same animal facility. During the one-year
study period, mortality was 37.5% for the homozygous E1-DN
mice, 12.5% for the heterozygous E1-DNmice, and 10% for the
wild-type mice.
2.2. Blood Glucose and Urine Albumin Measurements. Ran-
dom-fed blood glucose values were measured from tail vein
with OneTouch Ultra Glucometer (Lifescan, Milpitas, CA,
USA). Urine was collected as 24-hour samples in individual
metabolic cages. The volume of urine was measured, and
albumin concentration determined with mouse albumin
ELISA kit (CellTrend, Luckenwalde, Germany).
2.3. Histology. Kidney samples were fixed in 10% formalin,
dehydrated, and embedded in paraffin. Sections (5𝜇m) were
deparaffinised, stained with haematoxylin-eosin or periodic
acid-Schiff (PAS) using standard procedures, and examined
with Nikon Eclipse 800microscope (Nikon Instruments Inc.,
Melville, NY, USA). Image-Pro Analyzer 6.0 (Media Cyber-
netics, Bethesda,MD,USA) softwarewas used tomeasure the
percentage of PAS-positive area in the glomerular tuft.
2.4. Immunohistochemistry. Immunoperoxidase stainingwas
performed as previously described [33] using anti-activated
caspase-3 (cleaved caspase-3, Asp175; Cell Signaling, Dan-
vers, MA, USA) and anti-Ki-67 IgGs (Bethyl Laboratories,
Montgomery, TX, USA) as primary antibodies, and VectaS-
tain EliteABCKit (Vector Laboratories, Burlingame,CA) and
3-amino-9-ethylcarbazole (AEC) reagent (Sigma-Aldrich, St.
Louis, MO, USA) for detection. Proliferation index was
defined as the percentage of Ki-67 positive tubular cells and
calculated from 100 microscope fields (approximately 10 000
cells) per mouse.
2.5. Immunofluorescence. Kidney samples were snap frozen
in Tissue-TekOCT-compound (Sakura, Alphen aan den Rijn,
The Netherlands). Sections (5 𝜇m) were fixed with ice-cold
acetone for 10 minutes, washed, blocked with CAS-block
(Zymed, South San Francisco, CA, USA), and incubated with
anti-nephrin GP-N2 (Progen Biotechnik GmbH, Heidel-
berg, Germany) and anti-activated caspase-3 (Cell Signaling)
IgGs diluted in ChemMate (Dako, Glostrup, Denmark) and
labeled with Alexafluor 488- and 555-conjugated secondary
antibodies (Invitrogen, Carlsbad, CA, USA). After mounting
in Moviol or Vectashield Mounting Medium (Vector Labo-
ratories), the slides were analyzed using Leica SP2 confocal
microscope (Leica Microsystems, Wetzlar, Germany). The
staining intensity of nephrin was measured from a stack of
five consecutive images using FIJI image analysis software
and divided by the glomerular area.
2.6. Electron Microscopy. Kidney cortical samples were fixed
in 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.2–
7.4) at room temperature for 2 h, followed by postfixation in
1% osmium tetroxide for 2 h, stained en-bloc in 1% uranyl
acetate in 10% ethanol for 1 h, dehydrated in ethanol, and
embedded in LX-112 (Ladd Research Industries, Williston,
VT). Thin sections were stained with uranyl acetate and lead
citrate and examined in a JEM-1400 Transmission Electron
Microscope (Jeol, Tokyo, Japan) equipped with Olympus-
SIS Morada digital camera (Olympus Soft Imaging Solutions
GmbH, Mu¨nster, Germany). The mesangial volume fraction,
defined asmesangial cells, extracellularmatrix, and theGBM,
was calculated by morphometric analysis adapted from the
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method in [34], using the Fiji Software. The thickness of the
GBM was measured from random capillary loops. Capillary
loops with obvious bulging were excluded from the analysis
to avoid overestimating the thickness of the GBM. The foot
process width was determined as described in [35]. Shortly,
the number of foot processes per capillary loop was counted,
divided by the length of the GBM, and multiplied by 𝜋/4.
The mesangial volume fraction and the foot process width
are expressed as averages of measurements of three capillary
loops per glomerulus.
2.7. Statistics. The data are presented as means ± standard
error of mean (SEM), unless stated otherwise. Significance of
the differences between the groups was evaluated by Student’s
unpaired 𝑡-test for normally distributed variables and by
Mann-Whitney 𝑈 test for nonnormally distributed variables
or in case of a small sample size. For analyzing the correlation,
Spearman’s rho test was used. 𝑃 < 0.05 was used as the limit
for statistical significance. Analyses were performed using
Excel (Microsoft, Redmond,WA,USA) or SPSS PASWStatis-
tics (version 18) (IBM, Armonk, NY, USA) software.
3. Results
3.1. Diabetic E1-DN Mice Develop Albuminuria. Monitoring
of the blood glucose levels showed that the homozygousmale
E1-DN mice were overtly diabetic, as reported previously
[31]. The blood glucose level was highest in young animals
and stayed elevated during the whole follow-up (Figure 1(a)).
The E1-DN heterozygous male mice were significantly hyper-
glycaemic at young age (Figure 1(a)), but at older age their
blood glucose levels gradually decreased. Bodyweight did not
differ significantly between the homozygous and wild-type
mice at any time point (data not shown). Urinary albumin
excretion and urine volumes were followed by 24-hour urine
collections in metabolic cages. The E1-DN homozygous mice
were polyuric when compared to the wild-type mice (Fig-
ure 1(b)). At young age also the heterozygous E1-DN mice
had increased urine volumes (Figure 1(b)), consistent with
the hyperglycaemia. An increase in albumin excretion rate
(AER) in homozygous E1-DN mice was detected at the age
of 10 weeks when compared to wild-type mice (Figure 1(c)).
At 20 weeks some of the homozygous E1-DNmice developed
massive albuminuria, in range of milligrams per 24 hours.
Substantial variation was detected between individual mice
in the homozygous E1-DN group; the mice with the highest
blood glucose values developed the most severe albuminuria,
and a strong correlation between the albumin excretion and
blood glucose was evident at 20 weeks (𝑟 = 0.71, 𝑃 < 0.001)
(Figure 1(d)).
3.2. E1-DN Mice Develop Mesangial Expansion and Glomeru-
lar Sclerosis. Mesangial expansion is a characteristic finding
of diabetic glomerulopathy.Mesangial area, visualized by PAS
staining, was found to be increased by 25% in the homozy-
gous E1-DNmice when compared to the wild-typemice (35%
versus 28%, 𝑃 < 0.01, Students 𝑡-test, 𝑛 = 30–70 glomeruli
per group) (Figures 2(a)–2(e)). Electron microscopy con-
firmed an increase of 22% in the mesangial volume fraction
in the homozygous E1-DN mice (36% versus 29%, 𝑃 < 0.05,
Students 𝑡-test, 𝑛 = 14–38 glomeruli per group) (Figure 2(f)).
In two homozygous E1-DN mice with the highest albumin
excretion, the mesangial matrix accumulation was classified
as focal, global nodular sclerosis by an expert pathologist who
examined the samples blinded from the genotypes.
3.3. Albuminuric E1-DN Mice Exhibit Tubular Changes. Flat-
tened tubular epithelial cells and dilated tubular lumens were
observed in the kidneys of albuminuric homozygous E1-DN
mice in which the albumin excretion exceeded 1000𝜇g/24 h
at 20weeks of age (Figures 3(a) and 3(b)). To study the tubular
injury further, we stained proliferating cells with an antibody
for Ki-67 (Figures 3(c) and 3(d)). Significantly increased
tubular proliferation was observed in the albuminuric E1-DN
mice (proliferation index 0.70%), compared to the control
mice in which only sporadic proliferating cells were detected
(proliferation index 0.18%) (𝑃 < 0.01, Student’s 𝑡-test, 𝑛 = 3-4
mice per group).
3.4. Podocyte Apoptosis Is Increased in E1-DN Mice. To study
whether apoptosis plays a role in the glomerular injury in
the E1-DNmice, apoptotic glomerular cells were stained with
an antibody for activated caspase-3. Apoptotic cells were
counted from 10 glomeruli from each mouse (𝑛 = 4–8 mice
per group) by two researchers independently. Increased num-
ber of apoptotic cells was detected in the glomeruli of E1-
DN homozygous mice when compared to wild-type and
heterozygous E1-DN mice both at the age of 20 weeks (6.5
versus 1.0 apoptotic cells per 10 glomeruli, 𝑃 < 0.02, Mann-
Whitney 𝑈 test), and in the oldest age group of 56-57 weeks
(9.8 versus 4.4 apoptotic cells per 10 glomeruli, 𝑃 < 0.02,
Mann-Whitney 𝑈 test) (Figures 4(a)–4(c)), although the
amount of apoptotic glomerular cells was sparse in all mice.
To characterize the nature of the apoptotic glomerular cells,
we performed a double labelling for cleaved caspase-3 and
nephrin revealing that the apoptotic cells were podocytes
(Figure 4(d)).
3.5. Nephrin Expression Is Reduced in Diabetic E1-DN Mice.
The expression of nephrin, the key molecule of the slit
diaphragm structure connecting the podocyte foot processes,
was studied by immunofluorescence staining and confocal
microscopy (Figures 5(a) and 5(b)). Measurement of nephrin
staining intensity indicated lower expression level in albu-
minuric homozygous E1-DN mice when compared to wild-
type mice (Figure 5(c)). The expression patterns of other
podocyte proteins examined, podocin and ZO-1, were not
altered (data not shown).
3.6. E1-DN Mice Develop Glomerular Basement Membrane
Thickening and Podocyte Foot Process Widening. Electron
microscopic analysis of kidneys from two wild-type mice
(age 50 weeks) and three homozygous E1-DN mice (age 40–
50 weeks) revealed irregular thickening and bulging of the
GBM and widening of the podocyte foot processes in the
homozygous E1-DN mice (Figures 6(a)–6(c)). The width of
the GBMwasmeasured from random capillary loops in areas
where the basement membrane was regularly shaped and
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Figure 1: E1-DN mice develop hyperglycaemia and albuminuria. (a) Blood glucose is elevated in male E1-DN homozygous (hoz) mice (𝑛 =
8–16) compared to the wild-type (wt) mice (𝑛 = 6–10) at all the time points, ∗∗𝑃 < 0.01, ∗𝑃 < 0.05. At 6-7 weeks of age also the male E1-DN
heterozygous (hez) mice (𝑛 = 14–23) are hyperglycaemic, ‡𝑃 < 0.01, but at 40 weeks their blood glucose does not differ from the wt. (b)
Urine volumes of the male E1-DN hoz (𝑛 = 9–16), hez (𝑛 = 7–16), and wt mice (𝑛 = 6–10). ∗∗𝑃 < 0.01 and ∗𝑃 < 0.05 for hoz versus wt,
‡
𝑃 < 0.01 for hez versus wt. (c) Increased albumin excretion rate (AER) is detected at both 10 and 20 weeks of age in the homozygous E1-DN
male mice, ∗∗𝑃 < 0.01. Heterozygous mice do not develop albuminuria. In (a)–(c), data are shown as mean ± SEM. Mann-Whitney 𝑈 test
was used to compare groups. (d) AER is correlated to blood glucose at 20 weeks of age, 𝑟 = 0.71, 𝑃 < 0.001 (Spearman’s rho), 𝑛 = 22. As the
upper limit of the glucometer is 33.3mM, the samples giving the “high” code were analysed as 33.3mM.
foot processes appeared structurally normal and was found
to be 43% higher in the E1-DN homozygous mice when
compared to wild-type mice (258 nm versus 370 nm, 𝑃 =
0.025, Mann-Whitney 𝑈 test, 𝑛 = 3–8 glomeruli per group)
(Figure 6(d)). Podocyte foot processes were also 45% wider
in these hyperglycaemic and albuminuric E1-DN mice when
compared to wild-type mice (423 nm versus 613 nm, 𝑃 =
0.013, Mann-Whitney 𝑈 test, 𝑛 = 9-10 glomeruli per group)
(Figure 6(e)).
4. Discussion
This study describes the development of albuminuria in rela-
tion to hyperglycaemia in the diabetic E1-DN mice, a trans-
genic mouse model expressing kinase-negative EGF-R in
pancreatic islets [31], and characterizes the pathologic chan-
ges in glomeruli including mesangial expansion and glom-
erular sclerosis, thickening of the GBM and widening of
foot processes in albuminuric mice. Increased apoptosis was
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Figure 2: E1-DN mice present mesangial expansion and glomerular sclerosis. (a) Periodic acid-Schiff (PAS) staining of normal glomerulus
of the wild-type mouse aged 50 weeks. ((b), (c)) Global mesangial expansion (arrows) is observed by PAS staining in the homozygous E1-DN
mice aged 20 weeks (b) and 40 weeks (c). (d) Global nodular sclerosis (arrowheads) is seen in an E1-DN homozygous mouse aged 50 weeks.
(e) The percentage of mesangial area in the glomerular tuft determined by morphometry of PAS-stained histological sections indicates an
increase of 25% in the homozygous (hoz) E1-DN mice when compared to wild-type (wt) mice (𝑛 = 30 glomeruli from three 50 weeks old
wild-type mice and 𝑛 = 70 glomeruli from seven 20–50 weeks old homozygous mice). (f) Morphometric analysis performed on images
obtained by transmission electron microscopy (TEM) confirms the increase of mesangial volume fraction by 22% in the glomeruli of E1-DN
homozygous mice (𝑛 = 14 glomeruli from two 50 weeks old wild-type mice and 𝑛 = 38 glomeruli from six 20–50 weeks old homozygous
mice). In ((e), (f)), bars show mean ± SEM. ∗∗𝑃 < 0.01, ∗𝑃 < 0.05, Student’s 𝑡-test. Scale bar: 25 𝜇m.
identified as one mechanism contributing to glomerular
injury. In addition to glomerular changes, the E1-DN mice
showed flattened tubular epithelium with dilated lumens and
increased proliferation of tubular cells.
The kinase-negative EGF-R is expressed in the 𝛽-cells of
the pancreatic islets, and it functions in a dominant nega-
tive manner, reducing phosphorylation of the endogenous
EGF-R in response to EGF family ligands, resulting in a
significantly reduced 𝛽-cell mass, low insulin production and
subsequently high blood glucose, and early-onset diabetes
[31]. The renal phenotype we now report is purely secondary
to the long-acting hyperglycaemia. As blood glucose levels
were higher in male E1-DN mice when compared to females,
and male mice are generally more prone to renal injury, only
male mice were examined in this study.
Thehomozygous E1-DNmice developed substantial albu-
minuria. The mean AER was 2.5-fold higher in the homo-
zygous E1-DN mice compared to the wild-type littermates
already at the age of 10 weeks and nearly five-fold higher
at 20 weeks. The most severely affected mice had over 10-
fold increase in AER.The individual variation in the levels of
albuminuria can be explained by the variation in the blood
glucose levels, as AER and blood glucose correlated at the
age of 20 weeks. This reflects also the human diabetes, where
hyperglycaemia is themain risk factor for diabetic nephropa-
thy, as shown in several clinical studies [36, 37]. Intracellular
excess of glucose is known to result in the formation of
reactive oxygen species, which in turn cause inflammation
and formation of advanced glycosylation end products [38].
Histological analyses revealed mesangial expansion and
tubular changes in diabetic E1-DN mice. Mesangial expan-
sion is an important factor in the progression of diabetic
nephropathy [15], and mainly due to mesangial matrix accu-
mulation, which can eventually lead to formation of nodular
sclerosis, called Kimmelstiel-Wilson nodules [16]. The most
severely affected E1-DN mice developed glomerular sclerosis
resembling human diabetic glomerulopathy. Also tubular
changes belong to the histological features of human diabetic
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Figure 3: Renal tubules of E1-DN mice show morphological changes and increased proliferation. ((a), (b)) Hematoxylin and eosin staining
shows flattened tubular epithelial cells in the albuminuric E1-DN homozygous mice (b) when compared to normal tall cuboidal epithelium
in the wild-type mice (a). ((c), (d)) Immunostaining for Ki-67 reveals only occasional proliferating cells in the wild-type mice (c), whereas in
the albuminuric E1-DN homozygous mice groups of proliferating cells are observed (d). Scale bar: 50 𝜇m ((a), (b)); 25𝜇m ((c), (d)).
nephropathy [12] and have been shown to predict disease
progression in patients with type 2 diabetes and overt pro-
teinuria [39]. Increased proliferation of tubular cells, possibly
representing an adaptivemechanism to injury, has previously
been observed to contribute to the renal enlargement in
streptozotocin-induced diabetes in rats [40] and has been
detected also in db/db mice [41]. The data is in line with the
results of this study, showing increased proliferation in the
tubules of the albuminuric E1-DN mice.
Increased glomerular apoptosis has previously been
observed in kidney samples of human patients with diabetes
[23] and streptozotocin-treated diabetic rats [42]. Further,
reactive oxygen species have been shown tomediate podocyte
apoptosis in the db/db mouse model [43]. We observed an
increasednumber of apoptotic cells in the glomeruli of homo-
zygous E1-DN mice and found that the apoptotic cells were
podocytes. Apoptosis was rare in both diabetic and control
mice, but as podocytes are terminally differentiated cells,
even a small increase in the rate of apoptosis could affect the
development of glomerular injury. Another mechanism for
podocyte loss in diabetes is detachment. A recent study [22]
described severe disruption and detachment of podocyte foot
processes in patients with type 1 diabetes, leading to denuded
areas of GBM, previously described in focal segmental glom-
erulosclerosis [44], and considered as part of the process
leading to glomerular sclerosis [45]. In the E1-DN mice, no
denuded areas of GBM were observed. However, podocyte
foot process widening, a known feature of diabetic nephropa-
thy [18, 19], was evident in the most albuminuric E1-DN
mice. In addition, structural analysis by electron microscopy
revealed thickening of the GBM, which is a well-documented
and early finding in human diabetic nephropathy [13, 15].The
measurements of the thickness of the GBM were performed
on areas where the GBM was of regular shape, but in
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Figure 4: E1-DNmice show increased podocyte apoptosis. ((a), (b)) Staining for cleaved caspase-3was used to identify apoptotic cells (arrows)
in the glomeruli of wild-type (a) and homozygous E1-DNmice (b). (c) Apoptosis of glomerular cells is detectedmore often in the homozygous
(hoz) E1-DN mice when compared to heterozygous (hez) and wild-type (wt) mice. Bars show the mean number of apoptotic cells per 10
glomeruli ± SEM, 𝑛 = 4–8 mice/group. ∗𝑃 < 0.02, Mann-Whitney 𝑈 test. (d) Confocal microscopy of kidney sections of 20 weeks old
homozygous E1-DN mice stained for nephrin (green) and cleaved caspase-3 (red) indicates that the apoptotic cells in the glomeruli are
podocytes. Scale bar: 25 𝜇m.
addition, areas of irregular bulging of the membrane were
observed.
The expression of nephrin was found to be decreased in
the glomeruli of the albuminuric E1-DN mice, consistent
with previous results obtained with the streptozotocinmouse
model [46]. Also in human diabetic nephropathy the expres-
sion of nephrin protein [47] and mRNA [48] have been
reported to be reduced and inversely correlated with the
degree of proteinuria [48]. Whether this is causative or sec-
ondary to the disease progression and podocyte injury
remains to be investigated. However, it has been suggested
that the downregulation of nephrin is a selective change, as
the expression of podocin, another podocyte protein, has
been reported to remain unchanged in diabetes in humans
[49], as well as in a diabetic mouse model [46]. Consistent
with that, the expression of podocin and ZO-1 were not
altered in immunofluorescence stainings of the E1-DNmouse
glomeruli.
When compared to other mouse models of diabetes,
E1-DNmice develop substantial albuminuria and glomerular
pathology. It is notable that the renal changes are caused
by hyperglycaemia instead of direct effects of the EGF-R
transgene, and thus the E1-DN mouse model mimics human
diabetes with poor glycaemic control. In addition, there is
no need to consider the possible toxic effects on kidney, like
in one of the most widely used murine models of diabetes,
streptozotocin-induced destruction of pancreatic𝛽-cells.The
other widely usedmodel, the db/dbmouse, is insulin resistant
and diabetic due to a mutation in the leptin receptor gene.
Db/db mice serve as a good model for type 2 diabetes and
albuminuria but do not develop severe glomerulopathy [25].
E1-DN mice are hypoinsulinemic [31] and show similarities
8 BioMed Research International
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Figure 5: Expression of nephrin is reduced in the glomeruli of E1-DN mice. ((a), (b)) Confocal microscopy of wild-type (wt) (a) and
homozygous (hoz) (b) E1-DN mouse kidney sections stained for nephrin. (c) Quantification of the expression level of nephrin in two wild-
type mice and three albuminuric homozygous mice, five glomeruli per mice, reveals that the expression of nephrin is significantly lower in
the E1-DN homozygous mice. Bars show mean ± SEM. ∗∗𝑃 < 0.01, Student’s 𝑡-test. Scale bar: 20 𝜇m.
with the OVE26 and Akita mice. The OVE26 is a promis-
ing mouse model of diabetic renal disease, overexpress-
ing calmodulin in the pancreatic 𝛽-cells in mice in FVB
background, and presenting high albuminuria, as well as
severe glomerular pathology [27]. The Akita mice have a
spontaneous mutation in insulin 2 gene and were originally
described to have a modest renal phenotype in C57BL/6
strain [50]. When Akita mice were crossed to FVB/NJ
background, they, however, developed high proteinuria and
moderate mesangial expansion [26]. Recent studies thus
indicate that the background strain of the mouse model is
extremely important for the development of renal injury and
that the FVB background is susceptible for renal disease.
The FVB background may contribute to the relatively severe
phenotype of the E1-DN mice.
One disadvantage of the E1-DN model is the large
phenotypic variation between the individual mice, although
the intensity of the renal phenotype is directly correlated
to the blood glucose levels. Thus, designing an intervention
study with the E1-DN mouse model would require a large
number of mice. Histological and structural changes develop
relatively late; the most severe changes reported here were
detected at the age of 50 weeks. This is common for many of
the mouse models and not surprising, considering that overt
human diabetic nephropathy usually develops after 15 to 20
years of diabetes duration.
5. Conclusions
The hyperglycaemic E1-DN mice develop substantial albu-
minuria and histological and structural changes including
mesangial expansion, thickening of the GBM, podocyte foot
process widening, and altered tubular epithelial cell mor-
phology and proliferation. Reduced expression of nephrin
and increased apoptosis of podocytes might contribute to the
development of glomerular injury. Altogether, these changes
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Figure 6: Electron microscopy indicates glomerular basement membrane thickening and podocyte foot process effacement in E1-DN mice.
(a) In wild-type mouse (age 50 weeks) podocyte foot processes (FP) line regularly the glomerular basement membrane (GBM) around the
capillary loops (CL). (b) In the E1-DN homozygous mouse (age 40 weeks) irregular thickening of the GBM (arrowheads) and podocyte foot
process widening (arrow) are observed. (c) Foot process widening (arrows) is observed in 50 weeks old E1-DN homozygous mouse. (d) GBM
is thicker in the E1-DN homozygous (hoz) mice (age 40–50 weeks) compared to the wild-type (wt) mice (age 50 weeks). The thickness of the
GBMwas calculated from three glomeruli in twowild-type and eight glomeruli in three homozygous E1-DNmice. (e) Podocyte foot processes
are wider in the homozygous E1-DN mice (40–50 weeks of age) compared to the wild-type mice (50 weeks of age). Foot process width was
calculated from 10 glomeruli in two wild-type and 9 glomeruli in three homozygous E1-DN mice. Bars show mean ± SEM. ∗𝑃 < 0.025,
Mann-Whitney 𝑈 test. Scale bar: 2 𝜇m.
are typical of human diabetic nephropathy, and the E1-DN
mice can serve as a good model to study the pathogenesis of
the diabetic renal disease.
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